# OnCo record nct03591510 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct03591510/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct03591510", "NCT03591510" ;
  schema:name "A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML"@en ;
  schema:description "A phase 2 trial of Midostaurin, Fludarabine, Cytarabine, Daunorubicin, Idarubicin and Mitoxantrone in acute myeloid leukaemia, run by Novartis Pharmaceuticals, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct03591510/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03591510> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2019-03-13" ;
  onco:cancers <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/aml-paediatric/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/midostaurin/>, <https://onco.cc/drugs/fludarabine/>, <https://onco.cc/drugs/cytarabine/>, <https://onco.cc/drugs/daunorubicin/>, <https://onco.cc/drugs/idarubicin/>, <https://onco.cc/drugs/mitoxantrone/> ;
  onco:companies <https://onco.cc/companies/novartis/> .